Tackling Endocrine Resistance in Breast Cancer

Video

This video reviews the mechanisms of acquired and upfront endocrine resistance in estrogen receptor–positive breast cancer as well as research into strategies for overcoming this resistance.

In this video, Ingrid A. Mayer, MD, MSCI, of the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, discusses mechanisms of acquired and upfront endocrine resistance in estrogen receptor (ER)-positive breast cancer as well as research into strategies for overcoming these types of resistance, including targeting the mTOR and PI3K pathways.

Mayer spoke on this subject during an education session at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held last month in Chicago.

Related Videos
A panel of 4 experts on lung cancer
A panel of 4 experts on lung cancer
Collaboration among nurses, social workers, and others may help in safely administering outpatient bispecific T-cell engager therapy to patients.
Immunotherapy may be an “elegant” method of managing colorectal cancer, says Gregory Charak, MD.
D. Ross Camidge, MD, PhD, spoke about how the approval of alectinib is the beginning of multiple other approvals for patients with ALK-positive NSCLC.
Nurses should be educated on cranial nerve impairment that may affect those with multiple myeloma who receive cilta-cel, says Leslie Bennett, MSN, RN.
Alexander Spira, MD, PhD, FACP, an expert on lung cancer
A panel of 4 experts on lung cancer
Treatment with cilta-cel may give patients with multiple myeloma “more time,” according to Ishmael Applewhite, BSN, RN-BC, OCN.
Nurses may need to help patients with multiple myeloma adjust to walking differently in the event of peripheral neuropathy following cilta-cel.
Related Content
67 Disparities in Regional Anesthesia Block Acceptance for Mastectomy With Reconstruction Surgery in a Standardized Setting

67 Disparities in Regional Anesthesia Block Acceptance for Mastectomy With Reconstruction Surgery in a Standardized Setting

May 4th 2024
Article
Timothy Chen, MD, highlights how technologies such as ZAP-X and proton therapy may improve outcomes for patients with cancer.

Applying Novel Radiotherapy Technology for Brain Tumors and Other Cancers

April 29th 2024
Podcast

Timothy Chen, MD, highlights how technologies such as ZAP-X and proton therapy may improve outcomes for patients with cancer.

Findings support the use of 18F-PSMA-1007 PET/CT in the preoperative workflow of intermediate- and high-risk prostate cancer.

18F-PSMA-1007 PET/CT Improves Staging Vs MRI in Prostate Cancer

May 3rd 2024
Article

Findings support the use of 18F-PSMA-1007 PET/CT in the preoperative workflow of intermediate- and high-risk prostate cancer.

Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.

Moving The Needle in Lung Cancer Management With Robotic-Assisted Surgery

April 22nd 2024
Podcast

Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.

Data also highlight a favorable overall survival trend with the acalabrutinib regimen in the phase 3 ECHO trial.

Acalabrutinib Combo Yields PFS Improvement Vs SOC in Mantle Cell Lymphoma

May 3rd 2024
Article

Data also highlight a favorable overall survival trend with the acalabrutinib regimen in the phase 3 ECHO trial.

Findings from a health disparities report may support new policies designed to narrow persistent racial and ethnic disparities in health outcomes.

Data Highlight Pervasive Racial/Ethnic Disparities in Health Care

May 3rd 2024
Article

Findings from a health disparities report may support new policies designed to narrow persistent racial and ethnic disparities in health outcomes.